Why the study?
Despite effective and low-cost diagnosis and treatment options, scalable evidence-based strategies have not achieved optimal cardiovascular risk reduction.
Population
Patients with high modifiable ASCVD risk despite access to care at a large academic health system
Comparison
ASCVD Risk Reduction Initiative prevention programme implementation
Design
Case study of a learning health system model
Key result
The ASCVD Risk Reduction Initiative combined randomized trials, quality improvement, and rapid cycle testing to develop a scalable cardiovascular risk reduction program.
Authors
Loading...
Supports testing of integrated ASCVD programs; leaves open real-world effectiveness before practice adoption.
A learning health system approach combining rapid cycle testing, quality improvement, and traditional trials can be utilized to develop and scale cardiovascular risk reduction programs.
Ashcraft et al. (2026) studied Atherosclerotic cardiovascular disease (ASCVD) risk (n=75,149). ASCVD Risk Reduction Initiative was evaluated on Systolic BP and LDL-C at 6 months post randomisation (for the planned effectiveness trial). The ASCVD Risk Reduction Initiative combined randomized trials, quality improvement, and rapid cycle testing to develop a scalable cardiovascular risk reduction program.